In this issue:
ALGONQUIN: belamaf-Pd efficacious in triple-class refractory MM
Real-world effectiveness of belamaf monotherapy in RRMM
Inhibition of pinocytosis may mitigate ocular toxicity with belamaf
Indirect comparison of front-line DRd vs VRd for transplant-ineligible disease
Myeloma XII: post-salvage ASCT consolidation/maintenance prolongs PFS
Pom-PACE may be an effective bridging therapy for aggressive relapsed disease
Good Practice Paper - the management of transplant-eligible high-risk myeloma
Mass spectrometry-based determination of MRD feasible
Steroid-free venetoclax combo promising
The ultra-high-risk gene LILRB4 is a promising novel target for immunotherapy
Please login below to download this issue (PDF)